Chapters authored
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Episodes of Acute exacerbation (AE) of Idiopathic Pulmonary fibrosis (IPF) are important events in the disease trajectory of IPF, associated with punctuated decline in lung function with significant mortality and morbidity associated with it. These episodes are idiosyncratic, and often unpredictable and may have triggers. Our diagnostic criteria for these events, etiology, pathogenesis, risk factors and management continue to evolve over the years, with limited availability of qualitative research data to help guide management. Outcome in general is poor with no well-defined therapy but prevention may be possible with use of Nintedanib. Our chapter aims to explore the contemporary knowledge of the key aspects of this disease entity.
Part of the book: Idiopathic Pulmonary Fibrosis
Role of Amikacin in the Management of Ventilator-Associated Pneumonia
Ventilator-associated pneumonia accounts for 60% of healthcare-associated infection deaths. It results from invasion of the lower respiratory tract by microorganisms and affects patients 48 hours after they have been intubated and have received mechanical ventilation. Prompt diagnosis using a combination of clinical, radiographic, microbiological, and laboratory assessment can help prevent exacerbation of symptoms and provide immediate treatment. Usage of antibiotics for therapy has proven clinically useful; however, emerging resistance of microorganisms to these medications has been continuously evolving. This article focuses on amikacin and how its emerging role in treating VAP has improved patient outcomes and increased their chances of recovery with minimal adverse effects.
Part of the book: Recent Updates in Intensive Care Medicine [Working title]